Search This Blog

Thursday, August 13, 2026

Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M

 

The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.

In a royalty purchase and sale pact with Royalty Pharma, Zealand Pharma has exchanged most of its economic interest in the investigational polycythemia vera drug rusfertide that it had once developed with Protagonist Therapeutics.

Under the terms of the agreement, announced Wednesday night, Zealand will get $50 million upfront and stands to receive up to $50 million more on the first anniversary of the deal’s closing. In exchange, Zealand will surrender most of its remaining economic interests in rusfertide—those it hadn’t already returned to ex-partner Protagonist—including regulatory and sales milestones, as well as certain royalties on yearly product sales.

In 2012, Zealand partnered with Protagonist to advance disulfide-rich peptide therapies, one of which would eventually be rusfertide. The deal leveraged Protagonist’s platform for targets of Zealand’s choosing, Genetic Engineering & Biotechnology News reported at the time. Zealand was in charge of all preclinical and clinical work, though Protagonist retained the option to co-finance and co-develop the resulting assets.

The collaboration was terminated in 2014, kicking off a years-long dispute about payments still owed to Zealand. The two companies came to a resolution in August 2021, with both parties agreeing to a reduced milestone structure, plus royalties, though specifics of this new arrangement remain undisclosed.

In 2024, Protagonist partnered with Takeda to develop and commercialize rusfertide. Takeda and Protagonist in March announced that the FDA accepted their new drug application for rusfertide, granting it priority review. A decision is expected in the third quarter of this year.

Under the Wednesday deal with Royalty, Zealand will only retain the right to 0.25% royalties on global sales of rusfertide in excess of $1.5 billion—a stipulation that Jefferies said shows that Zealand expects rusfertide’s future sales to exceed current forecasts.

The terms of the Royalty deal suggest “consensus may underestimate the drug’s commercial potential,” the firm told investors late on Wednesday, pointing to the approximately $1.2 billion forecast by Takeda’s 2034 fiscal year.

“While the undisclosed milestones prevent a precise valuation analysis, Zealand’s decision to retain royalty exposure only above $1.5bn suggests it sees a realistic path to sales exceeding that level,” Jefferies said. The group has high expectations for rusfertide, pegging peak sales to hit around $2 billion.

Designed to be given subcutaneously every week, rusfertide works by mimicking the hormone hepcidin, which helps regulate the production of red blood cells. This mechanism addresses the underlying iron dysregulation in polycythemia vera, in turn lowering the excess production of red blood cells that is characteristic of the blood cancer, according to Zealand’s Wednesday release.

Phase 3 data released in March last year showed a 77% response rate in patients on rusfertide versus 33% in placebo comparators. Participants were on background treatment with standard of care. Rusfertide likewise significantly boosted the proportion of patients who didn’t need phlebotomy from weeks 20 through 32.

https://www.biospace.com/deals/zealand-sells-milestone-royalty-rights-to-rare-blood-cancer-asset-for-up-to-100m

Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale

 

PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms.

Amid the throes of bankruptcy, Sangamo Therapeutics has agreed to divest its Fabry disease program and a clutch of other assets and technologies to PTC Therapeutics and Eli Lilly.

Following a court-approved bidding process, Sangamo will sell its investigational Fabry disease gene therapy isaralgagene civaparvovec to PTC for $111 million at closing, as well as up to $100 million in potential milestone payments. Lilly, meanwhile, will pay $50 million for Sangamo’s zinc finger, capsid delivery and molecular integrase platforms, as well as the biotech’s prion disease program, according to a Wednesday release.

Other bidders are also buying select Sangamo tools and equipment for a collective $2.55 million.

These asset sales are still subject to a final court approval, but once closed, Sangamo is looking at around $163.55 million, plus up to $100 million in future milestones. The confirmation hearing for these deals is slated for the third quarter.

“Any proceeds ultimately received from the asset sales will be administered and distributed in accordance with the Chapter 11 process and applicable orders of the Bankruptcy Court,” a Sangamo spokesperson told BioSpace in an email on Wednesday.

In early June, Sangamo kicked off a strategic evaluation of its business, which resulted in a voluntary bankruptcy petition a few weeks later. Sangamo at the time also announced that it had agreed to sell its prion program and select technologies to Lilly, while Astellas had emerged as a potential buyer for the Fabry asset. It is unclear why the Astellas agreement fell through, but PTC has now been named the winning bidder for the rare disease program.

Following its initial bankruptcy announcement in June, Sangamo said that it would downsize by around 40%, a cut that affected 51 employees. “Beyond those actions, Sangamo has not announced any additional workforce reductions related to the proposed transactions with PTC Therapeutics and Lilly,” the spokesperson told BioSpace.

Isaralgagene civaparvovec is an investigational gene therapy that uses an adeno-associated viral vector to deliver a DNA construct that encodes for the alpha-galactosidase enzyme, according to Sangamo’s website. In patients with Fabry, mutations to the GLA gene lead to deficiencies in alpha-galactosidase activity, resulting in the toxic buildup of certain byproducts in tissues across the body, giving rise to symptoms such as numbness, pain, hearing loss and swelling.

Phase 1/2 data demonstrated improved kidney function, cardiac function and quality of life in patients dosed with the gene therapy. There is an ongoing rolling biologics license application filing with the FDA, which is planned for completion in the fourth quarter, according to PTC’s announcement of its agreement with Sangamo.

Meanwhile, Sangamo’s prion program, which is still in preclinical development, uses zinc fingers to protect neurons from misfolded prion proteins, in turn slowing or halting neurodegeneration, the biotech said on its website.

https://www.biospace.com/deals/bankrupt-sangamo-offloads-assets-to-lilly-ptc-in-161m-sale

US Disabilities Hit An All-Time High Of 37 Million In July: UP 23% Since Feb 2021

 by Ed Dowd via Beyond The Narrative,

The latest Bureau of Labor Statistics data is out, and the number of Americans ages 16 and over reporting a disability has hit a new all-time high of roughly 37 million. As of July 2026, the Current Population Survey series sits at 37,029,000. That's not a rounding error or a seasonal blip. It's the continuation of a trend that broke higher more than five years ago and has refused to mean-revert.

I've been tracking this series since early in the COVID era. The charts have been public for years on the Phinance Technologies site and in repeated threads on X. Month after month the total population with a disability grinds higher. From the pre-2020 plateau into early 2021 the numbers were relatively stable. Then something changed.

February 2021 marks the clear inflection. The rate of increase shifted to a new, steeper trajectory, a 3-to-4 sigma departure from the prior trend. In the years since, the survey has added seven million people. Growth of that magnitude in a mature population is not normal aging, not "long COVID" in isolation, and not some gradual sociological shift. It was sudden. It has persisted. And it continues to be treated as background noise by the same public health authorities who spent years obsessed with every other metric.

Let me address the predictable objections, because they surface every time these numbers are posted. First: "It's just fraud. People are gaming disability benefits." That claim collapses under basic scrutiny of the data source. This is not Social Security Disability Insurance claims. It is not SSDI awards, which lag, require medical determinations, and are subject to administrative backlogs and incentive effects. This is the Current Population Survey, the same monthly household survey that produces the unemployment rate and labor-force participation numbers. Roughly 60,000 households are contacted each month. Six simple questions are asked about serious difficulty hearing, seeing, concentrating/remembering/making decisions, walking or climbing stairs, dressing or bathing, and doing errands alone. Any "yes" classifies the person as having a disability for statistical purposes.

I laid this out in detail years ago in threads that are still easy to find. The series is real-time, not claims-driven, and has nothing to do with benefit eligibility. The questions have been consistent since 2008. Response patterns do not suddenly invent millions of new disabled respondents because the political winds shifted. When the same survey that markets, banks, and the Federal Reserve rely upon for labor-market signals produces a multi-year, multi-sigma break in disability prevalence, the responsible reaction is investigation, not dismissal.

Second: "It's illegal aliens flooding the numbers." This one is equally weak. Undocumented immigrants have long been known to under-respond or avoid government surveys altogether out of fear of detection, deportation risk, or general distrust of authorities. They are not lining up to answer detailed questions about household members' health limitations over the phone or in person. If anything, the survey systematically undercounts this population relative to reality. The sharp, sustained rise in reported disability began in February 2021, well before the largest recent surges in border encounters, and has continued in a manner inconsistent with simple demographic inflows. The data do not support the claim that the disability spike is an artifact of illegal immigration.

Public health agencies and the media have largely ignored the signal. There has been no serious, transparent inquiry into why the disability rate changed slope so sharply in early 2021 and has remained elevated. Temporary explanations such as COVID itself, lockdowns, mental-health effects of isolation all fail the timing and magnitude tests. The virus was already circulating in 2020 without producing this sustained break. The sharpest acceleration aligned with the mass rollout and subsequent workplace mandates. Correlation is not causation; we are constantly reminded. Fair enough, but when a novel medical intervention is administered to hundreds of millions of working-age adults on an accelerated timeline, and the independent, high-frequency survey of population health then records a multi-sigma regime change precisely then, the burden of proof shifts. Authorities who spent years demanding every other correlation be investigated suddenly lose interest.

The economic implications are not abstract. More than 37 million people reporting disability means a permanently larger share of the population facing barriers to full participation. Labor-force participation among the disabled remains far lower than among those without disability. Employers face higher absence rates and higher costs. Insurance pools absorb elevated claims. The fiscal pressure on entitlement programs grows even if this particular survey is not the claims pipeline. All of it is occurring against a backdrop of demographic aging that was already expected to raise disability prevalence gradually but not at the abrupt rate observed since early 2021.

I have posted the charts for years: total population 16+, the civilian labor force subset, men, women, employed versus not. The pattern is consistent. Rate-of-change moderation appears occasionally, then another leg higher. The February 2021 inflection remains the defining feature. A 3-to-4 sigma shift in trend is not something serious analysts discard. It is the kind of signal that, in any other domain...markets, epidemiology, engineering...would trigger immediate forensic review.

Health authorities have chosen another path. The data continues to accumulate. The total population survey keeps printing higher numbers. The questions asked of households have not changed. The methodology is the same one used for the official employment statistics that move markets every month. Yet the disability series is treated as an inconvenience rather than a red flag.

The conclusion from the data is straightforward. The timing, the magnitude, the concentration among the previously healthy working age population, and the failure of alternative explanations all point to the COVID vaccine campaign as one of the primary driver of the excess disability. That is the assessment I have maintained as the numbers have updated. Ignoring a sustained, multi-sigma break in a core government survey does not make the break disappear. It only guarantees that the consequences continue to compound while institutions look the other way.

The July 2026 print at 37 million is simply the latest confirmation. The trend that began in February 2021 has not been explained by health authorities, has not been investigated with appropriate rigor, and has not been reversed. Until that changes, the data will keep speaking whether anyone in authority cares to listen or not.

https://www.zerohedge.com/medical/dowd-us-disabilities-hit-all-time-high-37-million-july-23-feb-2021

BioStem liquidity, looming milestone payment remain concerns with raised 2026 revenue guidance

 

BioStem Q2 2026 EPS -$0.52 misses, revenue $7.9M beats estimates as company raises 2026 revenue guidance on hospital growth



Wolfe Research upgrades Abbott Laboratories to Outperform with $130 price target

 


  • Firm cites stronger 2027 growth drivers, including electrophysiology and Libre CGM catalysts, for the rating upgrade.

Wednesday, August 12, 2026

X suspends account of Houthi military spokesman Yahya Saree

 

X suspended the account of Yahya Saree, military spokesman for Yemen’s Iran-backed Houthis.

The profile, which had more than 121,000 followers, displayed a notice saying it had been suspended for violating the platform’s rules.

Saree regularly used the account to announce Houthi attacks on vessels in the Red Sea, as well as operations targeting Saudi Arabia and forces of Yemen’s internationally recognized government.

Taiwan holds anti-blockade naval drills

 The Taiwanese military held anti-blockade naval drills during the annual Han Kuang military exercises, the island's Ministry of National Defense said on Thursday.

The exercise included the Navy and the Coast Guard.

Meanwhile, the ministry reported the presence of 18 jets and 14 ships linked to the Chinese military near Taiwan's shores.

https://breakingthenews.net/Article/Taiwan-holds-anti-blockade-naval-drills/66910125